Download fulltext
HTML
1.
Mohammadi H, Rafii-Tabar H. Editorial – Application of Nanoscopic Quantum Systems in Retinal Restoration. JOVR [Internet]. 2024Mar.10 [cited 2024Apr.27];19(1):1–3. Available from: https://knepublishing.com/index.php/JOVR/article/view/15415
https://doi.org/10.18502/jovr.v19i1.15415
statistics
- 192 Abstract Views
- 141 PDF Views
- 0 HTML Views
authors
-
Hadi Mohammadi
Hadi Mohammadi
Department of Medical Physics and Biomedical Engineering, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
-
Hashem Rafii-Tabar
Hashem Rafii-Tabar
Department of Medical Physics and Biomedical Engineering, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Published Date
- Mar 10, 2024
Editorial – Application of Nanoscopic Quantum Systems in Retinal Restoration
Abstract
This is an Editorial and does not have an abstract. Please download the PDF or view the article in HTML.
Keywords:
N/A
References
1. Wang AL, Knight DK, Thanh-thao TV, Mehta MCJIoc. Retinitis pigmentosa: Review of current treatment. Int Opthalmol Clin 2019;59:263–280.
2. García-Layana A, Cabrera-López F, García-Arumí J, Arias- Barquet L, Ruiz-Moreno JMJCiia. Early and intermediate age-related macular degeneration: Update and clinical review. Clin Interv Aging 2017;12:1579–1587.
3. Pennington KL, DeAngelis MM. Epidemiology of agerelated macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 2016:3:34.
4. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RPJBJoO. Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br J Ophthalmol 2020;104:1077–1084.
5. Mata NL, Vogel RJCoio. Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 2010;21:190–196.
6. Schmidt-Erfurth U, Hasan TJSoo. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195–214.
7. Holz FG, Schmitz-Valckenberg S, Fleckenstein MJTJoci. Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014;124:1430–1438.
8. da Cruz L, Dorn JD, Humayun MS, Dagnelie G, Handa J, Barale P-O, et al. Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial. Ophthalmology 2016;123:2248–2254.
9. Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, et al. Subretinal visual implant alpha IMS – Clinical trial interim report. Vision Res 2015;111:149–160.
10. Winter JO, Cogan SF, Rizzo J. Retinal prostheses: Current challenges and future outlook. J Biomater Sci Polym Ed 2007;18:1031–1055.
11. Picaud S, Sahel J-A. Retinal prostheses: Clinical results and future challenges. C R Biol 2014;337:214–222.
12. Schmid EW, Fink W, Wilke R. Operational challenges of retinal prostheses. Med Eng Phys 2014;36:1644–1655.
13. Zeng Q, Huang Z. Challenges and opportunities of implantable neural interfaces: From material, electrochemical and biological perspectives. Adv Funct Mater 2023;33:2301223.
14. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine for the treatment of retinal and optic nerve diseases. Curr Opin Pharmacol 2013;13:134–148.
15. Zarbin MA, Arlow T, Ritch R. Regenerative nanomedicine for vision restoration. Mayo Clin Proc 2013;88:1480–1490.
16. Gómez-Garzón M, Martínez-Ceballos MA, Gómez-López A, Rojas-Villarraga A. Application of nanotechnology in ophthalmology: Where are we? Charact Appl Nanomater 2022;5:66–78.
17. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: The new frontier. Am J Ophthalmol 2010;150:144–162.e2.
18. Tang Z, Fan X, Chen Y, Gu P. Ocular nanomedicine. Adv Sci 2022;9:e2003699.
19. Herrera-Barrera M, Ryals RC, Gautam M, Jozic A, Landry M, Korzun T, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv 2023;9:eadd4623.
20. Chien Y, Hsiao Y-J, Chou S-J, Lin T-Y, Yarmishyn AA, Lai W-Y, et al. Nanoparticles-mediated CRISPRCas9 gene therapy in inherited retinal diseases: Applications, challenges, and emerging opportunities. J Nanobiotechnology 2022;20:511.
21. Tawfik M, Chen F, Goldberg JL, Sabel BA, et al. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. Naunyn Schmiedebergs Arch Pharmacol 2022;395:1477–1507.
22. Eleftheriou CG, Zimmermann JB, Kjeldsen HD, David-Pur M, Hanein Y, Sernagor E. Carbon nanotube electrodes for retinal implants: A study of structural and functional integration over time. Biomaterials 2017;112:108–121.
23. Bareket L, Waiskopf N, Rand D, Lubin G, David-Pur M, Ben- Dov J, et al. Semiconductor nanorod–carbon nanotube biomimetic films for wire-free photostimulation of blind retinas. Nano Lett 2014;14:6685–6692.
24. Riva ER, Micera S. Section 4–Nanotechnology-based neuronal interfaces. p. 16.
25. Zhao D, Huang R, Gan J-M, Shen Q-D. Photoactive nanomaterials for wireless neural biomimetics, stimulation, and regeneration. ACS Nano 2022;16:19892–19912.
26. Choi C, Choi MK, Liu S, Kim M, Park OK, Im C, et al. Human eye-inspired soft optoelectronic device using high-density MoS2-graphene curved image sensor array. Nat Comm 2017;8:1664.
27. Ghaffari M, Moztarzadeh S, Rahmanian F, Yazdanpanah A, Ramedani A, Mills DK, et al. Nanobiomaterials for bionic eye: Vision of the future. Eng Nanobiomater 2016;2:257– 285.
28. Tang J, Qin N, Chong Y, Diao Y, Yiliguma, Wang Z, et al. Nanowire arrays restore vision in blind mice. Nat Commun 2018;9:786.
29. Jackson TL, Mandava N, Quiroz-Mercado H, Benage M, Garcia-Aguirre G, Morales-Canton V, et al. Intravitreal quantum dots for retinitis pigmentosa: A first-in-human safety study. Nanomedicine 2021;16:617–626.
30. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969–976.
31. Olson JL, Velez-Montoya R, Mandava N, Stoldt CR. Intravitreal silicon-based quantum dots as neuroprotective factors in a model of retinal photoreceptor degeneration. Invest Ophthalmol Vis Sci 2012;53:5713–5721.
32. Olson J, Velez-Montoya R, Mandava N, Stoldt CR. Neuroprotective effect of photoactive quantum dots in progressive retinal photoreceptor degeneration. J Nanomater Mol Nanotechnol 2013;7:2.
2. García-Layana A, Cabrera-López F, García-Arumí J, Arias- Barquet L, Ruiz-Moreno JMJCiia. Early and intermediate age-related macular degeneration: Update and clinical review. Clin Interv Aging 2017;12:1579–1587.
3. Pennington KL, DeAngelis MM. Epidemiology of agerelated macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 2016:3:34.
4. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RPJBJoO. Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br J Ophthalmol 2020;104:1077–1084.
5. Mata NL, Vogel RJCoio. Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 2010;21:190–196.
6. Schmidt-Erfurth U, Hasan TJSoo. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195–214.
7. Holz FG, Schmitz-Valckenberg S, Fleckenstein MJTJoci. Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014;124:1430–1438.
8. da Cruz L, Dorn JD, Humayun MS, Dagnelie G, Handa J, Barale P-O, et al. Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial. Ophthalmology 2016;123:2248–2254.
9. Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, et al. Subretinal visual implant alpha IMS – Clinical trial interim report. Vision Res 2015;111:149–160.
10. Winter JO, Cogan SF, Rizzo J. Retinal prostheses: Current challenges and future outlook. J Biomater Sci Polym Ed 2007;18:1031–1055.
11. Picaud S, Sahel J-A. Retinal prostheses: Clinical results and future challenges. C R Biol 2014;337:214–222.
12. Schmid EW, Fink W, Wilke R. Operational challenges of retinal prostheses. Med Eng Phys 2014;36:1644–1655.
13. Zeng Q, Huang Z. Challenges and opportunities of implantable neural interfaces: From material, electrochemical and biological perspectives. Adv Funct Mater 2023;33:2301223.
14. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine for the treatment of retinal and optic nerve diseases. Curr Opin Pharmacol 2013;13:134–148.
15. Zarbin MA, Arlow T, Ritch R. Regenerative nanomedicine for vision restoration. Mayo Clin Proc 2013;88:1480–1490.
16. Gómez-Garzón M, Martínez-Ceballos MA, Gómez-López A, Rojas-Villarraga A. Application of nanotechnology in ophthalmology: Where are we? Charact Appl Nanomater 2022;5:66–78.
17. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: The new frontier. Am J Ophthalmol 2010;150:144–162.e2.
18. Tang Z, Fan X, Chen Y, Gu P. Ocular nanomedicine. Adv Sci 2022;9:e2003699.
19. Herrera-Barrera M, Ryals RC, Gautam M, Jozic A, Landry M, Korzun T, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv 2023;9:eadd4623.
20. Chien Y, Hsiao Y-J, Chou S-J, Lin T-Y, Yarmishyn AA, Lai W-Y, et al. Nanoparticles-mediated CRISPRCas9 gene therapy in inherited retinal diseases: Applications, challenges, and emerging opportunities. J Nanobiotechnology 2022;20:511.
21. Tawfik M, Chen F, Goldberg JL, Sabel BA, et al. Nanomedicine and drug delivery to the retina: Current status and implications for gene therapy. Naunyn Schmiedebergs Arch Pharmacol 2022;395:1477–1507.
22. Eleftheriou CG, Zimmermann JB, Kjeldsen HD, David-Pur M, Hanein Y, Sernagor E. Carbon nanotube electrodes for retinal implants: A study of structural and functional integration over time. Biomaterials 2017;112:108–121.
23. Bareket L, Waiskopf N, Rand D, Lubin G, David-Pur M, Ben- Dov J, et al. Semiconductor nanorod–carbon nanotube biomimetic films for wire-free photostimulation of blind retinas. Nano Lett 2014;14:6685–6692.
24. Riva ER, Micera S. Section 4–Nanotechnology-based neuronal interfaces. p. 16.
25. Zhao D, Huang R, Gan J-M, Shen Q-D. Photoactive nanomaterials for wireless neural biomimetics, stimulation, and regeneration. ACS Nano 2022;16:19892–19912.
26. Choi C, Choi MK, Liu S, Kim M, Park OK, Im C, et al. Human eye-inspired soft optoelectronic device using high-density MoS2-graphene curved image sensor array. Nat Comm 2017;8:1664.
27. Ghaffari M, Moztarzadeh S, Rahmanian F, Yazdanpanah A, Ramedani A, Mills DK, et al. Nanobiomaterials for bionic eye: Vision of the future. Eng Nanobiomater 2016;2:257– 285.
28. Tang J, Qin N, Chong Y, Diao Y, Yiliguma, Wang Z, et al. Nanowire arrays restore vision in blind mice. Nat Commun 2018;9:786.
29. Jackson TL, Mandava N, Quiroz-Mercado H, Benage M, Garcia-Aguirre G, Morales-Canton V, et al. Intravitreal quantum dots for retinitis pigmentosa: A first-in-human safety study. Nanomedicine 2021;16:617–626.
30. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969–976.
31. Olson JL, Velez-Montoya R, Mandava N, Stoldt CR. Intravitreal silicon-based quantum dots as neuroprotective factors in a model of retinal photoreceptor degeneration. Invest Ophthalmol Vis Sci 2012;53:5713–5721.
32. Olson J, Velez-Montoya R, Mandava N, Stoldt CR. Neuroprotective effect of photoactive quantum dots in progressive retinal photoreceptor degeneration. J Nanomater Mol Nanotechnol 2013;7:2.